Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections - The first Ciproxan® IV special investigation in 2001

Japanese Journal of Antibiotics

Volumn 56, Issue 6, 2003, Pages 546-573

  Yamaguchi, Keizo ^a   Ishii, Yoshikazu ^a   Yamanaka, Kiyoharu ^b   Watanabe, Naoki ^c   Uehara, Nobuyuki ^c   Kaku, Mitsuo ^d   Hayashi, Mutsumu ^e   Iinuma, Yoshitsugu ^f   Ichiyama, Satoshi ^g   Kurokawa, Yukinori ^h   Hirakata, Yoichi ⁱ  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Otemae Hospital   (Japan)

^c SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f NAGOYA UNIVERSITY HOSPITAL   (Japan)

^g KYOTO UNIVERSITY HOSPITAL   (Japan)

^h KAWASAKI MEDICAL SCHOOL   (Japan)

ⁱ NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFMETAZOLE; CEFOPERAZONE; CEFOTIAM; CEFOZOPRAN; CEFTAZIDIME; CEPHEM; CIPROFLOXACIN; ERYTHROMYCIN; FLOMOXEF; GENTAMICIN; GLUCOSE; IMIPENEM; MEROPENEM; METICILLIN; MINOCYCLINE; OXACILLIN; PANIPENEM; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TEICOPLANIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; DILUTION; DISEASE SEVERITY; DRUG APPROVAL; DRUG FORMULATION; DRUG SENSITIVITY; ENTEROBACTERIACEAE; ENTEROCOCCUS AVIUM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYME SYNTHESIS; FERMENTATION; HUMAN; LIQUID; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; POSTMARKETING SURVEILLANCE; PSEUDOMONAS AERUGINOSA; SPECIES; STANDARD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CIPROFLOXACIN; DOSAGE FORMS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS; JAPAN; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 9144274935     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Japanese Journal of Antibiotics 54(8): 401-447, 2001
2. Chemotherapy 41: 184-189, 1993
3. Chemotherapy 42: 905-914, 1994
4. Chemotherapy 45: 757-761, 1997
5. YAGI, T.; H. KUROKAWA, S. ICHIYAMA, et al.: Nosocomial spread of cephem-resistant Escherichia coli strains carrying multiple toho-1-like β-lactamase genes. Antimicrobial Agents and Chemotherapy 41(12): 2606-2611, 1997
6. PERILLI, M.; E. DELL'AMICO, B. SEGATORE, et al.: Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian Nationwide Survey. Journal of Clinical Microbiology 40(2): 611-614, 2002
7. IMP) in Gram-negative rods resistant to broad-spectrum β-lactams. Journal of Clinical Microbiology 34(12): 2909-2913, 1996
8. YAN, J.; P. HSUEH, W. KO, et al.: Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrobial Agents and Chemotherapy 45(8): 2224-2228, 2001
9. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that growaerobically-Fourth edition. Approved standard M7-A4. NCCLS., Villanova, Pa., 1999
10. YOKOTA, S.; K. SATO, O. Kuwahara, et al.: Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrobial Agents and Chemotherapy 46: 3311-3315, 2002
11. Japanese Journal of Antibiotics 55(4): 370-398, 2002
12. Japanese Journal of Antibiotics 55(6): 800-807, 2002
13. IMP. Antimicrobial Agents and Chemotherapy 42(8): 2006-2011, 1998
14. HAYAMI, H., T. GOTO., M. KAWAHARA, et al.: Activities of β-Lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isoleted from complicated urinary tract infections. J. Infect. Chemother. 5: 130-138, 1999
15. KRUMPE, P. E.; S. COHN, J. GARRELTES, et al.: Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Journal of Antimicrobial Chemotherapy 43 (Suppl. A): 117-128, 1999
16. YAGI, T.; H. KUROKAWA, N. SHIBATA, et al.: A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol. Lett. 1; 184(1): 53-56, 2000
17. KOMATSU, M.; N. IKEDA, M. AIHARA, et al.: Hospital outbreak of MEN-1-derived extended spectrum β-lactamase-producing Klebsiella pneumoniae. J. Infect. Chemother. 7(2): 94-101, 2001
18. SENDA, K.; Y. ARAKAWA, K. NAKASHIMA, et al.: Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrobial Agents and Chemotherapy 40(2): 349-353, 1996